Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
Hyperuricaemia is associated with an increased risk of gout, kidney stones and cardiovascular disease. The present post hoc analysis of pooled data from four placebo‐controlled phase III studies assessed the effect of canagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, on serum uric acid lev...
Gespeichert in:
| Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2015-04, Vol.17 (4), p.426-429 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 429 |
|---|---|
| container_issue | 4 |
| container_start_page | 426 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 17 |
| creator | Davies, M. J. Trujillo, A. Vijapurkar, U. Damaraju, C. V. Meininger, G. |
| description | Hyperuricaemia is associated with an increased risk of gout, kidney stones and cardiovascular disease. The present post hoc analysis of pooled data from four placebo‐controlled phase III studies assessed the effect of canagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, on serum uric acid levels in patients with type 2 diabetes mellitus (T2DM) and in a subset of patients with hyperuricaemia [defined as baseline serum uric acid ≥475 µmol/l (∼8 mg/dl)]. At week 26, canagliflozin 100 and 300 mg were associated with a ∼13% reduction in serum uric acid compared with placebo. In the subset of patients with hyperuricaemia, placebo‐subtracted percent reductions in serum uric acid were similar to those in the overall cohort. More patients in the hyperuricaemic group achieved a serum uric acid level of |
| doi_str_mv | 10.1111/dom.12439 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5054919</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3059443952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5099-c79a12aade31e604f0ed659405fc18a5fd70510836c1dc8303ca8d2cd0ae7b0f3</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhSNERR-w4A8gS2xgkfb6GWeDVJVSKgaK0CCWlseP1iWJBztpmf76mk47AiTwxpb93aNzfKrqOYZ9XNaBjf0-Joy2j6odzAStMSXi8d2Z1LIFsl3t5nwJAIzK5km1TbgAIEzuVPNj750ZUfTI6EGfd8F38SYMKA4ouzT1aErBIG2CReV2qcfghjGj6zBeoHG1dIggG_TCjS6j3nVdGKf8tNryusvu2f2-V319dzw_el_Pzk5Ojw5nteHQtrVpWo2J1tZR7AQwD84K3jLg3mCpubcNcAySCoOtkRSo0dISY0G7ZgGe7lVv1rrLadE7a4qzpDu1TKHXaaWiDurPlyFcqPN4pThw1uK2CLy6F0jxx-TyqPqQTUmhBxenrLAQRDAAiQv68i_0Mk5pKPEUhWK6_D4n_6OKFpZCsIYX6vWaMinmnJzfWMagfjWqSqPqrtHCvvg944Z8qLAAB2vgOnRu9W8l9fbs44NkvZ4IeXQ_NxM6fVeioQ1X3z6dqObL59kcA1Ef6C3GArkV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1661866475</pqid></control><display><type>article</type><title>Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Davies, M. J. ; Trujillo, A. ; Vijapurkar, U. ; Damaraju, C. V. ; Meininger, G.</creator><creatorcontrib>Davies, M. J. ; Trujillo, A. ; Vijapurkar, U. ; Damaraju, C. V. ; Meininger, G.</creatorcontrib><description>Hyperuricaemia is associated with an increased risk of gout, kidney stones and cardiovascular disease. The present post hoc analysis of pooled data from four placebo‐controlled phase III studies assessed the effect of canagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, on serum uric acid levels in patients with type 2 diabetes mellitus (T2DM) and in a subset of patients with hyperuricaemia [defined as baseline serum uric acid ≥475 µmol/l (∼8 mg/dl)]. At week 26, canagliflozin 100 and 300 mg were associated with a ∼13% reduction in serum uric acid compared with placebo. In the subset of patients with hyperuricaemia, placebo‐subtracted percent reductions in serum uric acid were similar to those in the overall cohort. More patients in the hyperuricaemic group achieved a serum uric acid level of <360 µmol/l (∼6 mg/dl) with both canagliflozin 100 mg (23.5%) and 300 mg (32.4%) compared with placebo (3.1%). Incidences of gout and kidney stones were low and similar across groups. In conclusion, canagliflozin treatment decreased serum uric acid in patients with T2DM, including those with baseline hyperuricaemia.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.12439</identifier><identifier>PMID: 25600248</identifier><identifier>CODEN: DOMEF6</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject><![CDATA[Adult ; Aged ; Antidiabetics ; Calculi ; canagliflozin ; Canagliflozin - administration & dosage ; Canagliflozin - adverse effects ; Canagliflozin - therapeutic use ; Cardiovascular diseases ; Cohort Studies ; Diabetes ; diabetes complications ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Dose-Response Relationship, Drug ; Down-Regulation ; drug mechanism ; Drug Therapy, Combination - adverse effects ; Drugs ; Female ; Glucose transporter ; Gout ; Gout - epidemiology ; Gout - etiology ; Gout - prevention & control ; Humans ; Hyperuricemia ; Hyperuricemia - complications ; Hyperuricemia - physiopathology ; Hyperuricemia - prevention & control ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Incidence ; Kidney Calculi - epidemiology ; Kidney Calculi - etiology ; Kidney Calculi - prevention & control ; Kidney stones ; Kidneys ; Male ; Middle Aged ; Nephrolithiasis ; Placebos ; Research Letter ; Research Letters ; Rheumatism ; Risk ; SGLT2 inhibitor ; Sodium-Glucose Transporter 2 - antagonists & inhibitors ; type 2 diabetes ; Uric acid ; Uric Acid - blood]]></subject><ispartof>Diabetes, obesity & metabolism, 2015-04, Vol.17 (4), p.426-429</ispartof><rights>2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.</rights><rights>2015 John Wiley & Sons Ltd.</rights><rights>2015 John Wiley & Sons Ltd</rights><rights>2015. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5099-c79a12aade31e604f0ed659405fc18a5fd70510836c1dc8303ca8d2cd0ae7b0f3</citedby><cites>FETCH-LOGICAL-c5099-c79a12aade31e604f0ed659405fc18a5fd70510836c1dc8303ca8d2cd0ae7b0f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdom.12439$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdom.12439$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25600248$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Davies, M. J.</creatorcontrib><creatorcontrib>Trujillo, A.</creatorcontrib><creatorcontrib>Vijapurkar, U.</creatorcontrib><creatorcontrib>Damaraju, C. V.</creatorcontrib><creatorcontrib>Meininger, G.</creatorcontrib><title>Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Hyperuricaemia is associated with an increased risk of gout, kidney stones and cardiovascular disease. The present post hoc analysis of pooled data from four placebo‐controlled phase III studies assessed the effect of canagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, on serum uric acid levels in patients with type 2 diabetes mellitus (T2DM) and in a subset of patients with hyperuricaemia [defined as baseline serum uric acid ≥475 µmol/l (∼8 mg/dl)]. At week 26, canagliflozin 100 and 300 mg were associated with a ∼13% reduction in serum uric acid compared with placebo. In the subset of patients with hyperuricaemia, placebo‐subtracted percent reductions in serum uric acid were similar to those in the overall cohort. More patients in the hyperuricaemic group achieved a serum uric acid level of <360 µmol/l (∼6 mg/dl) with both canagliflozin 100 mg (23.5%) and 300 mg (32.4%) compared with placebo (3.1%). Incidences of gout and kidney stones were low and similar across groups. In conclusion, canagliflozin treatment decreased serum uric acid in patients with T2DM, including those with baseline hyperuricaemia.</description><subject>Adult</subject><subject>Aged</subject><subject>Antidiabetics</subject><subject>Calculi</subject><subject>canagliflozin</subject><subject>Canagliflozin - administration & dosage</subject><subject>Canagliflozin - adverse effects</subject><subject>Canagliflozin - therapeutic use</subject><subject>Cardiovascular diseases</subject><subject>Cohort Studies</subject><subject>Diabetes</subject><subject>diabetes complications</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Down-Regulation</subject><subject>drug mechanism</subject><subject>Drug Therapy, Combination - adverse effects</subject><subject>Drugs</subject><subject>Female</subject><subject>Glucose transporter</subject><subject>Gout</subject><subject>Gout - epidemiology</subject><subject>Gout - etiology</subject><subject>Gout - prevention & control</subject><subject>Humans</subject><subject>Hyperuricemia</subject><subject>Hyperuricemia - complications</subject><subject>Hyperuricemia - physiopathology</subject><subject>Hyperuricemia - prevention & control</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Incidence</subject><subject>Kidney Calculi - epidemiology</subject><subject>Kidney Calculi - etiology</subject><subject>Kidney Calculi - prevention & control</subject><subject>Kidney stones</subject><subject>Kidneys</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nephrolithiasis</subject><subject>Placebos</subject><subject>Research Letter</subject><subject>Research Letters</subject><subject>Rheumatism</subject><subject>Risk</subject><subject>SGLT2 inhibitor</subject><subject>Sodium-Glucose Transporter 2 - antagonists & inhibitors</subject><subject>type 2 diabetes</subject><subject>Uric acid</subject><subject>Uric Acid - blood</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp9kUtv1DAUhSNERR-w4A8gS2xgkfb6GWeDVJVSKgaK0CCWlseP1iWJBztpmf76mk47AiTwxpb93aNzfKrqOYZ9XNaBjf0-Joy2j6odzAStMSXi8d2Z1LIFsl3t5nwJAIzK5km1TbgAIEzuVPNj750ZUfTI6EGfd8F38SYMKA4ouzT1aErBIG2CReV2qcfghjGj6zBeoHG1dIggG_TCjS6j3nVdGKf8tNryusvu2f2-V319dzw_el_Pzk5Ojw5nteHQtrVpWo2J1tZR7AQwD84K3jLg3mCpubcNcAySCoOtkRSo0dISY0G7ZgGe7lVv1rrLadE7a4qzpDu1TKHXaaWiDurPlyFcqPN4pThw1uK2CLy6F0jxx-TyqPqQTUmhBxenrLAQRDAAiQv68i_0Mk5pKPEUhWK6_D4n_6OKFpZCsIYX6vWaMinmnJzfWMagfjWqSqPqrtHCvvg944Z8qLAAB2vgOnRu9W8l9fbs44NkvZ4IeXQ_NxM6fVeioQ1X3z6dqObL59kcA1Ef6C3GArkV</recordid><startdate>201504</startdate><enddate>201504</enddate><creator>Davies, M. J.</creator><creator>Trujillo, A.</creator><creator>Vijapurkar, U.</creator><creator>Damaraju, C. V.</creator><creator>Meininger, G.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201504</creationdate><title>Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus</title><author>Davies, M. J. ; Trujillo, A. ; Vijapurkar, U. ; Damaraju, C. V. ; Meininger, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5099-c79a12aade31e604f0ed659405fc18a5fd70510836c1dc8303ca8d2cd0ae7b0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antidiabetics</topic><topic>Calculi</topic><topic>canagliflozin</topic><topic>Canagliflozin - administration & dosage</topic><topic>Canagliflozin - adverse effects</topic><topic>Canagliflozin - therapeutic use</topic><topic>Cardiovascular diseases</topic><topic>Cohort Studies</topic><topic>Diabetes</topic><topic>diabetes complications</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Down-Regulation</topic><topic>drug mechanism</topic><topic>Drug Therapy, Combination - adverse effects</topic><topic>Drugs</topic><topic>Female</topic><topic>Glucose transporter</topic><topic>Gout</topic><topic>Gout - epidemiology</topic><topic>Gout - etiology</topic><topic>Gout - prevention & control</topic><topic>Humans</topic><topic>Hyperuricemia</topic><topic>Hyperuricemia - complications</topic><topic>Hyperuricemia - physiopathology</topic><topic>Hyperuricemia - prevention & control</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Incidence</topic><topic>Kidney Calculi - epidemiology</topic><topic>Kidney Calculi - etiology</topic><topic>Kidney Calculi - prevention & control</topic><topic>Kidney stones</topic><topic>Kidneys</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nephrolithiasis</topic><topic>Placebos</topic><topic>Research Letter</topic><topic>Research Letters</topic><topic>Rheumatism</topic><topic>Risk</topic><topic>SGLT2 inhibitor</topic><topic>Sodium-Glucose Transporter 2 - antagonists & inhibitors</topic><topic>type 2 diabetes</topic><topic>Uric acid</topic><topic>Uric Acid - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Davies, M. J.</creatorcontrib><creatorcontrib>Trujillo, A.</creatorcontrib><creatorcontrib>Vijapurkar, U.</creatorcontrib><creatorcontrib>Damaraju, C. V.</creatorcontrib><creatorcontrib>Meininger, G.</creatorcontrib><collection>Istex</collection><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Davies, M. J.</au><au>Trujillo, A.</au><au>Vijapurkar, U.</au><au>Damaraju, C. V.</au><au>Meininger, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2015-04</date><risdate>2015</risdate><volume>17</volume><issue>4</issue><spage>426</spage><epage>429</epage><pages>426-429</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><coden>DOMEF6</coden><abstract>Hyperuricaemia is associated with an increased risk of gout, kidney stones and cardiovascular disease. The present post hoc analysis of pooled data from four placebo‐controlled phase III studies assessed the effect of canagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, on serum uric acid levels in patients with type 2 diabetes mellitus (T2DM) and in a subset of patients with hyperuricaemia [defined as baseline serum uric acid ≥475 µmol/l (∼8 mg/dl)]. At week 26, canagliflozin 100 and 300 mg were associated with a ∼13% reduction in serum uric acid compared with placebo. In the subset of patients with hyperuricaemia, placebo‐subtracted percent reductions in serum uric acid were similar to those in the overall cohort. More patients in the hyperuricaemic group achieved a serum uric acid level of <360 µmol/l (∼6 mg/dl) with both canagliflozin 100 mg (23.5%) and 300 mg (32.4%) compared with placebo (3.1%). Incidences of gout and kidney stones were low and similar across groups. In conclusion, canagliflozin treatment decreased serum uric acid in patients with T2DM, including those with baseline hyperuricaemia.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>25600248</pmid><doi>10.1111/dom.12439</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2015-04, Vol.17 (4), p.426-429 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5054919 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Antidiabetics Calculi canagliflozin Canagliflozin - administration & dosage Canagliflozin - adverse effects Canagliflozin - therapeutic use Cardiovascular diseases Cohort Studies Diabetes diabetes complications Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Dose-Response Relationship, Drug Down-Regulation drug mechanism Drug Therapy, Combination - adverse effects Drugs Female Glucose transporter Gout Gout - epidemiology Gout - etiology Gout - prevention & control Humans Hyperuricemia Hyperuricemia - complications Hyperuricemia - physiopathology Hyperuricemia - prevention & control Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Incidence Kidney Calculi - epidemiology Kidney Calculi - etiology Kidney Calculi - prevention & control Kidney stones Kidneys Male Middle Aged Nephrolithiasis Placebos Research Letter Research Letters Rheumatism Risk SGLT2 inhibitor Sodium-Glucose Transporter 2 - antagonists & inhibitors type 2 diabetes Uric acid Uric Acid - blood |
| title | Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T11%3A06%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20canagliflozin%20on%20serum%20uric%20acid%20in%20patients%20with%20type%202%20diabetes%20mellitus&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Davies,%20M.%20J.&rft.date=2015-04&rft.volume=17&rft.issue=4&rft.spage=426&rft.epage=429&rft.pages=426-429&rft.issn=1462-8902&rft.eissn=1463-1326&rft.coden=DOMEF6&rft_id=info:doi/10.1111/dom.12439&rft_dat=%3Cproquest_pubme%3E3059443952%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1661866475&rft_id=info:pmid/25600248&rfr_iscdi=true |